Myriad to File sPMA to the US FDA of BRACAnalysis CDx as a Companion Diagnostic for Lynparza (olaparib) to Treat Metastatic Castrate-Resistant Prostate Cancer in Men

 Myriad to File sPMA to the US FDA of BRACAnalysis CDx as a Companion Diagnostic for Lynparza (olaparib) to Treat Metastatic Castrate-Resistant Prostate Cancer in Men

Shots:

  • Myriad to seek approval based on the P-III PROfound results assessing Lynparza vs enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have failed prior treatment with the hormonal agent with homologous recombination repair gene mutations
  • In 2007, Myriad & AstraZeneca entered into collaboration on Lynparza and has resulted in multiple regulatory approvals for BRACAnalysis CDx as companion diagnostic of Lynparza
  • BRACAnalysis CDx is an in vitro diagnostic intended to detect & classify variants in the protein-coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes utilizing genomic DNA obtained from blood specimen collected in EDTA

Click here to­ read full press release/ article | Ref: Globe NewsWire | Image: Pharma Journalist

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post